63 episodes
In conversation with... The Lancet Gastroenterology & Hepatology
-
- Science
-
-
5.0 • 1 Rating
-
Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.
-
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.
Read the full article:
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5) -
Dan Turner on vedolizumab in children with IBD
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.
Read the full article:
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS) -
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.
Read the full article:
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT) -
James Alexander on immune responses to COVID-19 vaccination in patients with IBD
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.
Read the full article:
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP) -
Filip Knop on liraglutide for bile acid diarrhoea
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.
Read the full article:
Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial -
Edward Kim on radiation segmentectomy for unresectable very early to early stage hepatocellular carcinoma
Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.
Read the full article:
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study
Customer Reviews
Top Podcasts In Science
You Might Also Like